|
1
|
Demonty G, Bernard-Marty C, Puglisi F, et
al: Progress and new standards of care in the management of HER-2
positive breast cancer. Eur J Cancer. 43:497–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Whenham N, D’Hondt V and Piccart MJ:
HER2-positive breast cancer: from trastuzumab to innovatory
anti-HER2 strategies. Clin Breast Cancer. 8:38–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yarden Y, Baselga J and Miles D: Molecular
approach to breast cancer treatment. Semin Oncol. 31(5 Suppl 10):
S6–S13. 2004. View Article : Google Scholar
|
|
4
|
Zhang ZJ and Ma SL: miRNAs in breast
cancer tumorigenesis (Review). Oncol Rep. 27:903–910. 2012.
|
|
5
|
Chia S, Norris B, Speers C, et al: Human
epidermal growth factor receptor 2 overexpression as a prognostic
factor in a large tissue microarray series of node-negative breast
cancers. J Clin Oncol. 26:5697–5704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Semiglazov VF and Semiglazov VV:
Neoadjuvant systemic therapy in breast cancer. Neoadjuvant
Chemotherapy: Current Applications in Clinical Practice. Bathe OF:
Intech; Rijeka: pp. 1–22. 2012
|
|
7
|
Semiglazov VF and Semiglazov VV:
Neoadjuvant (Preoperative) Therapy in Breast Cancer. 2013
|
|
8
|
von Minckwitz G, Untch M, Blohmer JU, et
al: Definition and impact of pathologic complete response on
prognosis after neoadjuvant chemotherapy in various intrinsic
breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coudert BP, Largillier R, Arnould L, et
al: Multicenter phase II trial of neoadjuvant therapy with
trastuzumab, docetaxel, and carboplatin for human epidermal growth
factor receptor-2–overexpressing stage II or III breast cancer:
results of the GETN (A)-1 trial. J Clin Oncol. 25:2678–2684. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galdy S, Zenoni D, Galmozzi A, et al:
Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide
chemotherapy in breast cancer: The TEC regimen. A retrospective
analysis. J Cancer Res Ther. 2:40–47. 2014.
|
|
11
|
Hirano A, Shimizu T, Watanabe O, et al:
Epirubicin and cyclophosphamide followed by docetaxel as primary
systemic chemotherapy in locally advanced breast cancer. Anticancer
Res. 28:4137–4142. 2008.
|
|
12
|
Yao X, Hosenpud J, Chitambar CR, et al: A
phase II study of concurrent docetaxel, epirubicin and
cyclophosphamide as a neoadjuvant chemotherapy regimen in patients
with locally advanced breast cancer. J Cancer. 3:145–151. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gianni L, Eiermann W, Semiglazov V, et al:
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant
trastuzumab versus neoadjuvant chemotherapy alone, in patients with
HER2-positive locally advanced breast cancer (the NOAH trial): a
randomised controlled superiority trial with a parallel
HER2-negative cohort. Lancet. 375:377–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pegram M and Liao J: Trastuzumab treatment
in multiple lines: current data and future directions. Clin Breast
Cancer. 12:10–18. 2012. View Article : Google Scholar
|
|
15
|
Greene FL and Sobin LH: A worldwide
approach to the TNM staging system: collaborative efforts of the
AJCC and UICC. J Surg Oncol. 99:269–272. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Luo Y, Gong Y, Liu Y, Qiu W and Tu
J: Clinical features and molecular phenotypes of breast cancer in
patients with type-2 diabetes mellitus. Asian Pac J Cancer Prev.
12:2183–2188. 2011.
|
|
17
|
Khabaz MN: Immunohistochemistry subtypes
(ER/PR/HER) of breast cancer: where do we stand in the West of
Saudi Arabia? Asian Pac J Cancer Prev. 15:8395–8400. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Modern Pathology. 11:155–168.
1998.PubMed/NCBI
|
|
19
|
Almasri NM and Al Hamad M:
Immunohistochemical evaluation of human epidermal growth factor
receptor 2 and estrogen and progesterone receptors in breast
carcinoma in Jordan. Breast Cancer Res. 7:R598–R604. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pauletti G, Godolphin W, Press MF and
Slamon DJ: Detection and quantitation of HER-2/neu gene
amplification in human breast cancer archival material using
fluorescence in situ hybridization. Oncogene. 13:63–72.
1996.PubMed/NCBI
|
|
21
|
Hayward JL, Carbone PP, Heuson JC, et al:
Assessment of response to therapy in advanced breast cancer: a
project of the Programme on Clinical Oncology of the International
Union Against Cancer, Geneva, Switzerland. European J Cancer.
13:89–94. 1977. View Article : Google Scholar
|
|
22
|
Huang D: TEC program neoadjuvant
chemotherapy for locally advanced breast cancer observed. Hebei
Med. 18:519–521. 2012.(In Chinese).
|
|
23
|
Herrada J, Iyer RB, Atkinson EN, Sneige N,
Buzdar AU and Hortobagyi GN: Relative value of physical
examination, mammography, and breast sonography in evaluating the
size of the primary tumor and regional lymph node metastases in
women receiving neoadjuvant chemotherapy for locally advanced
breast carcinoma. Clin Cancer Res. 3:1565–1569. 1997.
|
|
24
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
et al: Recommendations from an international expert panel on the
use of neoadjuvant (primary) systemic treatment of operable breast
cancer: an update. J Clin Oncol. 24:1940–1949. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu Q, Xia S, Li C and Yu S: Analysis of
long-term cardiotoxicity of adjuvant trastuzumab therapy in 26
HER2-positive breast cancer patients. Chin J Clin Oncol.
29:1952–1955. 2012.(In Chinese).
|
|
26
|
Guo L, Hou X, Dilimina Y and Wang B:
Expression of ERβ, ERα and Her-2 and distribution of molecular
subtypes in Uygur and Han patients with breast cancer. Exp Ther
Med. 7:1077–1082. 2014.PubMed/NCBI
|
|
27
|
Untch M, Fasching PA, Konecny GE, et al:
Pathologic complete response after neoadjuvant chemotherapy plus
trastuzumab predicts favorable survival in human epidermal growth
factor receptor 2-overexpressing breast cancer: results from the
TECHNO trial of the AGO and GBG study groups. J Clin Oncol.
29:3351–3357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lazaridis G, Pentheroudakis G and Pavlidis
N: Integrating trastuzumab in the neoadjuvant treatment of primary
breast cancer: accumulating evidence of efficacy, synergy and
safety. Crit Rev Oncol Hematol. 66:31–41. 2008. View Article : Google Scholar
|
|
29
|
Slamon D, Eiermann W, Robert N, et al;
Breast Cancer International Research Group. Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esteva FJ, Valero V, Booser D, et al:
Phase II study of weekly docetaxel and trastuzumab for patients
with HER-2-overexpressing metastatic breast cancer. J Clin Oncol.
20:1800–1808. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marty M, Cognetti F, Maraninchi D, et al:
Randomized phase II trial of the efficacy and safety of trastuzumab
combined with docetaxel in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer administered as
first-line treatment: the M77001 study group. J Clin Oncol.
23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Montemurro F, Choa G, Faggiuolo R, et al:
Safety and activity of docetaxel and trastuzumab in HER2
overexpressing metastatic breast cancer: a pilot phase II study. Am
J Clin Oncol. 26:95–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tedesco KL, Thor AD, Johnson DH, et al:
Docetaxel combined with trastuzumab is an active regimen in HER-2
3+ overexpressing and fluorescent in situ hybridization-positive
metastatic breast cancer: a multi-institutional phase II trial. J
Clin Oncol. 22:1071–1077. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Untch M, Rezai M, Loibl S, et al:
Neoadjuvant treatment with trastuzumab in HER2-positive breast
cancer: results from the GeparQuattro Study. J Clin Oncol.
28:2024–2031. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mauri D, Pavlidis N and Ioannidis JP:
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a
meta-analysis. J Nat Cancer Inst. 97:188–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wolmark N, Wang J, Mamounas E, Bryant J
and Fisher B: Preoperative chemotherapy in patients with operable
breast cancer: nine-year results from National Surgical Adjuvant
Breast and Bowel Project B-18. J Natl Cancer Inst Monogr.
30:96–102. 2001. View Article : Google Scholar
|
|
37
|
Suter TM, Procter M, van Veldhuisen DJ, et
al: Trastuzumab-associated cardiac adverse effects in the herceptin
adjuvant trial. J Clin Oncol. 25:3859–3865. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baselga J, Norton L, Albanell J, Kim YM
and Mendelsohn J: Recombinant humanized anti-HER2 antibody
(Herceptin) enhances the antitumor activity of paclitaxel and
doxorubicin against HER2/neu overexpressing human breast cancer
xenografts. Cancer Res. 58:2825–2831. 1998.PubMed/NCBI
|
|
39
|
Palmer BV, Walsh GA, McKinna JA and
Greening WP: Adjuvant chemotherapy for breast cancer: side effects
and quality of life. Br Med J. 281:1594–1597. 1980. View Article : Google Scholar : PubMed/NCBI
|
